# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-206390
Filing Date
2026-05-05
Accepted
2026-05-05 16:09:25
Documents
58
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | trvi-20260331.htm iXBRL | 10-Q | 1557556
2 | EX-10.1 | trvi-ex10_1.htm | EX-10.1 | 28834
3 | EX-31.1 | trvi-ex31_1.htm | EX-31.1 | 18099
4 | EX-31.2 | trvi-ex31_2.htm | EX-31.2 | 18088
5 | EX-32.1 | trvi-ex32_1.htm | EX-32.1 | 12329
6 | EX-32.2 | trvi-ex32_2.htm | EX-32.2 | 12304
7 | GRAPHIC | img64809683_0.jpg | GRAPHIC | 41981
| Complete submission text file | 0001193125-26-206390.txt |  | 7376721

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | trvi-20260331.xsd | EX-101.SCH | 932631
62 | EXTRACTED XBRL INSTANCE DOCUMENT | trvi-20260331_htm.xml | XML | 1430237

Mailing Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 16TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 26943135
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)